Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody engineered in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification results in a fucose-deficient antibody, significantly enhancing its antibody-dependent cellular cytotoxicity (ADCC) capabilities. Specifically designed to target CD19, Inebilizumab demonstrates increased efficacy in mediating ADCC against B cells. This product is ideal for advanced research applications focusing on immune-mediated diseases such as multiple sclerosis and neuromyelitis optica, providing a valuable tool for studies into the pathogenesis and treatment of these conditions.
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody engineered in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification results in a fucose-deficient antibody, significantly enhancing its antibody-dependent cellular cytotoxicity (ADCC) capabilities. Specifically designed to target CD19, Inebilizumab demonstrates increased efficacy in mediating ADCC against B cells. This product is ideal for advanced research applications focusing on immune-mediated diseases such as multiple sclerosis and neuromyelitis optica, providing a valuable tool for studies into the pathogenesis and treatment of these conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
